Cue Biopharma (NASDAQ:CUE) Trading 9% Higher – What’s Next?

Cue Biopharma, Inc. (NASDAQ:CUE) shot up 9% during mid-day trading on Friday . The stock traded as high as $0.3067 and last traded at $0.3020. 1,314,008 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 2,017,854 shares. The stock had previously closed at $0.2770.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cue Biopharma in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Cue Biopharma Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.66. The stock has a fifty day moving average price of $0.46 and a two-hundred day moving average price of $0.66. The company has a market cap of $23.78 million, a P/E ratio of -0.66 and a beta of 1.47.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $2.15 million for the quarter, compared to analysts’ expectations of $2.29 million. Cue Biopharma had a negative return on equity of 271.67% and a negative net margin of 530.75%. On average, equities analysts forecast that Cue Biopharma, Inc. will post -0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cue Biopharma

Institutional investors have recently bought and sold shares of the stock. GC Wealth Management RIA LLC bought a new position in Cue Biopharma in the 2nd quarter valued at about $2,273,000. Boothbay Fund Management LLC bought a new stake in shares of Cue Biopharma during the 3rd quarter worth about $439,000. Angeles Wealth Management LLC acquired a new stake in shares of Cue Biopharma in the 2nd quarter worth approximately $82,000. Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma in the 3rd quarter worth approximately $62,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.